Epidemiology of Diabetes Mellitus in Patients With Psoriatic Arthritis: Current Evidence
- 1Department of Dermatology Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine Shanghai China
- 2Institute of Dermatology Shanghai Academy of Traditional Chinese Medicine Shanghai China
Abstract
Aims: Diabetes mellitus (DM) is a common comorbidity of psoriatic arthritis (PsA); however, its global prevalence and the impact of treatment exposure remain unclear. This study aimed to assess the global prevalence of DM in patients with PsA using different subgroup analyses.
Materials and Methods: A systematic search of PubMed, Embase, the Cochrane Library and the Web of Science was performed from inception until February 2025 for observational studies reporting the prevalence or incidence of DM in PsA patients. Random‐effects models were applied to pool estimates, and subgroup, meta‐regression, and sensitivity analyses were conducted to explore heterogeneity. Publication bias was evaluated using the Egger's test and the trim‐and‐fill method.
Results: Sixty‐three studies, including 293,582 patients with PsA, were analysed. Patients with PsA included in this study were divided into treatment‐disclosed and non‐treatment‐disclosed groups. DM overall prevalence in patients with PsA was 13.84% in the non‐treatment‐disclosed population and 13.50% in the treatment‐disclosed cohort. Geographically, the comorbidity prevalence rates were higher in South America (37.98%) and Asia (16.76%) than in Europe (12.81%) and North America (12.38%) in the non‐treatment‐disclosed population. In the treatment‐disclosed population, prevalence was also highest in South America (28.13%), followed by Asia (18.30%). Meta‐regression analysis identified age, type of DM, region, and study design as contributors to heterogeneity. Evidence of small‐study effects was detected in the T2DM subgroup and cohorts receiving systemic therapy plus biologics.
Conclusions: Subgroup analysis shows that the prevalence of DM is associated with the type of study and the region in which the patients were located. These findings support routine metabolic screening for PsA and highlight the need for longitudinal studies to track disease activity, treatment patterns, and metabolic outcomes.
Related
- Limited Joint Mobility Syndrome Mimicking Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus: A Case Report
- Clinic-Based Proportion of Psoriatic Arthritis and HLA-B27 Distribution in Korean Psoriasis Patients: A Retrospective Study.
- A Multi-Axis Plantar Load Measurement Platform for the Assessment of Foot Disorders: Comparison of Patients With Psoriatic Arthritis to a Healthy Control Cohort.
- Diagnostic performance of FIB-4 in detecting advanced liver fibrosis in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis using methotrexate.
- Sex-specific outcomes in methotrexate therapy among patients with psoriatic arthritis and psoriasis.
BibTeX
@article{wang2026epidemiology,
title = {{Epidemiology of Diabetes Mellitus in Patients With Psoriatic Arthritis: Current Evidence}},
author = {Jiao Wang and Xuan Zhou and Jiale Chen and Qingyun Wang and Xiaofei Yi and Pengbo Gao and Jingjie He and Shufen Yang and Miao Zhang and Xiaoying Sun and Liu Liu and Xin Li},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
month = oct,
doi = {10.1002/dmrr.70239},
url = {https://doi.org/10.1002/dmrr.70239},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Epidemiology of Diabetes Mellitus in Patients With Psoriatic Arthritis: Current Evidence
AU - Jiao Wang
AU - Xuan Zhou
AU - Jiale Chen
AU - Qingyun Wang
AU - Xiaofei Yi
AU - Pengbo Gao
AU - Jingjie He
AU - Shufen Yang
AU - Miao Zhang
AU - Xiaoying Sun
AU - Liu Liu
AU - Xin Li
PY - 2026
DA - 2026/10/27
JO - Diabetes/Metabolism Research and Reviews
DO - 10.1002/dmrr.70239
UR - https://doi.org/10.1002/dmrr.70239
AB - Aims: Diabetes mellitus (DM) is a common comorbidity of psoriatic arthritis (PsA); however, its global prevalence and the impact of treatment exposure remain unclear. This study aimed to assess the global prevalence of DM in patients with PsA using different subgroup analyses. Materials and Methods: A systematic search of PubMed, Embase, the Cochrane Library and the Web of Science was performed from inception until February 2025 for observational studies reporting the prevalence or incidence of DM in PsA patients. Random‐effects models were applied to pool estimates, and subgroup, meta‐regression, and sensitivity analyses were conducted to explore heterogeneity. Publication bias was evaluated using the Egger's test and the trim‐and‐fill method. Results: Sixty‐three studies, including 293,582 patients with PsA, were analysed. Patients with PsA included in this study were divided into treatment‐disclosed and non‐treatment‐disclosed groups. DM overall prevalence in patients with PsA was 13.84% in the non‐treatment‐disclosed population and 13.50% in the treatment‐disclosed cohort. Geographically, the comorbidity prevalence rates were higher in South America (37.98%) and Asia (16.76%) than in Europe (12.81%) and North America (12.38%) in the non‐treatment‐disclosed population. In the treatment‐disclosed population, prevalence was also highest in South America (28.13%), followed by Asia (18.30%). Meta‐regression analysis identified age, type of DM, region, and study design as contributors to heterogeneity. Evidence of small‐study effects was detected in the T2DM subgroup and cohorts receiving systemic therapy plus biologics. Conclusions: Subgroup analysis shows that the prevalence of DM is associated with the type of study and the region in which the patients were located. These findings support routine metabolic screening for PsA and highlight the need for longitudinal studies to track disease activity, treatment patterns, and metabolic outcomes.
SN - 1520-7552
SN - 1520-7560
ER -